Valuation: Vistagen Therapeutics, Inc.

Market Cap 13.18M 11.59M 10.96M 9.94M 18.67M 1.27B 18.78M 131M 50.69M 646M 49.48M 48.41M 2.07B P/E 2027 *
-0.2x
P/E 2028 * -0.19x
Enterprise Value 13.18M 11.59M 10.96M 9.94M 18.67M 1.27B 18.78M 131M 50.69M 646M 49.48M 48.41M 2.07B EV / Sales 2027 *
7.75x
EV / Sales 2028 * -
Free-Float
99.62%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Vistagen Therapeutics, Inc.

1 day+8.79%
1 week+27.47%
Current month+16.47%
1 month+17.44%
3 months-57.69%
6 months-47.83%
Current year-55.13%
1 week 0.26
Extreme 0.26405
0.55
1 month 0.23
Extreme 0.226
0.55
Current year 0.2
Extreme 0.198
0.8
1 year 0.2
Extreme 0.198
5.14
3 years 0.2
Extreme 0.198
5.86
5 years 0.2
Extreme 0.198
83.4
10 years 0.2
Extreme 0.198
135
Manager TitleAgeSince
Chief Executive Officer 63 2009-07-31
Director of Finance/CFO 53 2025-11-30
Chief Tech/Sci/R&D Officer 57 2026-05-17
Director TitleAgeSince
Director/Board Member 63 1999-12-31
Chairman 90 2000-05-31
Director/Board Member 58 2019-01-09
Date Insider Type Main position Quantity % Market Cap. Importance
7/29/26 Free

Director

40,826 0.0995%
6/30/26 Free

Chief Executive Officer

36,818 0.0897%
6/30/26 Free

Chief Financial Officer

11,712 0.0285%
Change 5-day change 1-year change 3-year change Capi.($)
+8.79%+27.47%-91.59%-94.27% 12.11M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
+0.75%+0.75%+36.71%+21.09% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-7.59% 20.74B
-1.70%+0.43%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
-2.53%-8.15%-6.38%+483.59% 14.23B
Average +0.68%+2.65%+24.54%+141.20% 27.52B
Weighted average by Cap. -0.12%-1.08%+38.13%+127.00%

Financials

2027 *2028 *
Net sales 1.7M 1.5M 1.41M 1.28M 2.41M 163M 2.42M 16.93M 6.54M 83.27M 6.38M 6.24M 268M -
Net income -61.56M -54.14M -51.2M -46.44M -87.21M -5.91B -87.71M -613M -237M -3.02B -231M -226M -9.69B -65.79M -57.86M -54.71M -49.63M -93.2M -6.31B -93.74M -655M -253M -3.22B -247M -242M -10.35B
Net Debt - -
Logo Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Employees
41
Date Price Change Volume
26-09-28 US$0.2970 +8.79% 6,023,101
26-09-25 US$0.2730 -7.46% 5,572,025
26-09-24 US$0.2950 -19.92% 20,471,724
26-09-23 US$0.3684 +46.54% 574,960,002
26-09-22 US$0.2514 +7.90% 5,999,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.2970USD
Average target price
1.000USD
Spread / Average Target
+236.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VTGN Stock